ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer
ImmunoGen, Inc. (IMGN)
Last immunogen, inc. earnings: 5/1 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.immunogen.com/investor-relations
Company Research
Source: Business Wire
Results to be Presented at 2019 ASCO Annual Meeting Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Platinum-Sensitive Patients WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin® (bevacizumab) in patients with folate receptor alpha (FRa)-positive platinum-resistant ovarian cancer. These findings will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31 – June 4 in Chicago, IL. “We are pleased that the com
Show less
Read more
Impact Snapshot
Event Time:
IMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMGN alerts
High impacting ImmunoGen, Inc. news events
Weekly update
A roundup of the hottest topics
IMGN
News
- Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Immunogen Inc SVP & CHIEF BUSINESS OFFICER Stacy Coen Sells 4,583 Shares [Yahoo! Finance]Yahoo! Finance
- ImmunoGen, Inc. (NASDAQ: IMGN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- AbbVie Sees Signs of Post-Humira Growth in Positive 2024 Outlook [BNN Bloomberg (Canada)]BNN Bloomberg
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
IMGN
Earnings
- 11/2/23 - Beat
IMGN
Sec Filings
- 2/12/24 - Form 4
- 2/12/24 - Form 4
- 2/12/24 - Form 4
- IMGN's page on the SEC website